< Terug naar vorige pagina


Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Tijdschriftbijdrage - Tijdschriftartikel

INTRODUCTION: The combination of a targeted biomolecule that specifically defines the target and a radionuclide that delivers a cytotoxic payload offers a specific way to destroy cancer cells. Targeted radionuclide therapy (TRNT) aims to deliver cytotoxic radiation to cancer cells and causes minimal toxicity to surrounding healthy tissues. Recent advances using α-particle radiation emphasizes their potential to generate radiation in a highly localized and toxic manner because of their high level of ionization and short range in tissue.

AREAS COVERED: We review the importance of targeted alpha therapy (TAT) and focus on nanobodies as potential beneficial vehicles. In recent years, nanobodies have been evaluated intensively as unique antigen-specific vehicles for molecular imaging and TRNT.

EXPERT OPINION: We expect that the efficient targeting capacity and fast clearance of nanobodies offer a high potential for TAT. More particularly, we argue that the nanobodies' pharmacokinetic properties match perfectly with the interesting decay properties of the short-lived α-particle emitting radionuclides Astatine-211 and Bismuth-213 and offer an interesting treatment option particularly for micrometastatic cancer and residual disease.

Tijdschrift: Expert Opin Biol Ther
ISSN: 1471-2598
Issue: 8
Volume: 16
Pagina's: 1035-47
Jaar van publicatie:2016
  • PubMed Central Id: PMC4940885
  • DOI: https://doi.org/10.1080/14712598.2016.1185412
  • Scopus Id: 84979076055
  • WoS Id: 000379936400007
  • ORCID: /0000-0002-9997-4571/work/61029049
  • ORCID: /0000-0002-6895-4260/work/61247254
  • ORCID: /0000-0003-1276-5855/work/61442920
  • ORCID: /0000-0003-3753-1895/work/61471743
  • ORCID: /0000-0002-1773-8664/work/62884245
  • ORCID: /0000-0001-9220-4833/work/88545751
CSS-citation score:3